scholarly journals Novel Multidisciplinary Comprehensive Clinic Program Improves Patient Compliance, Patient Satisfaction and Health Maintainance Outcomes in the Outpatient Setting for Patients with Severe Sickle Cell Disease

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 4937-4937
Author(s):  
Paul Gordon ◽  
Ramamoorthy Nagasubramanian ◽  
Ashley Parker ◽  
Lindsay Clark ◽  
Hayley Balmer ◽  
...  

Abstract Introduction Sickle Cell Disease (SCD) is the most common genetic disease identified in newborns in the United States. It results from a single amino acid substitution in the beta globin protein. This results in severe chronic complications, long-term end-organ damage and reduced life expectancy. Evidence Based Health Maintenance (HM) recommendations (HMR) provide the best framework for reducing chronic complications of SCD. Many barriers to healthcare utilization exists for patients with SCD and patients are often unable to access HMR. The decrease in comprehensive care often leads to poor compliance and outcomes. To address this we established a novel patient centered comprehensive SCD clinic (CSCDC). Methods CSCDC occurs the third Wednesday of every month. Sub-specialists commit to CSCDC and subspecialty clinic slots are reserved. Available services: Cardiology, Radiology, Ophthalmology, Pulmonology, Nephrology, Social Work, Immunizations. Other services are available as needed. Lunch and group patient education are provided. There are 188 SCD patients in our program (the cohort). This includes HbSS, HbSC and HbSB thalassemia only. Patients electronic charts are reviewed to determine HM needs. Families are contacted by phone 4-6 weeks prior to the scheduled CSCDC. The HM needs are reviewed with families. The family has an opportunity to adjust work, school and other personal commitments in advance of the clinic date. Family and SCD clinic commits to the CSCDC date. Clinic flexibility is allowed. Electronic medical records and Qlik Sense Software (Qlik ,Randor PA) were used to determine visit numbers and clinic no show rates (NSR). Patient initiated same day cancellations are included in the NSR. NSR date range was January 2016-July 2018. First we determined NSR for all SCD related clinic visits for the cohort (NSR-SCD). Then we determined NSR for the cohort on CSCDC dates only (NSR-CSCDC). We then divided the cohort into three groups based on NSR-SCD. Low, middle and high NSR. We then compared NSR-SCD and NSR-CSCDC for each group. The two proportion Z test was used to calculate p values Volunteers unrelated to CSCDC contacted patients by telephone. Prior IRB approval was obtained. Family participation was voluntary and limited to families with CSCDC attendance. Parents or patients (18 years and older) were asked to answer questions. The questions evaluated 1.Patient overall satisfaction with CSCDC, 2.Likely to return to CSCDC, 3.Likely to recommend CSCDC and 4.Did CSCDC improve the patients individual SCD management. CSCDC dates Aug 2015-July 2018 were used to select the sub-cohort of patients that attended two or more CSCDC clinics. We determined if the HM evaluations occurred according to published guidelines. Results There was a statistically significant decrease in NSR for patients attending CSCDC vs the general SCD clinic. The cohort consisted of 188 patients, 1243 clinic visits and 322 no shows(NS). In CSCDC there were 134 patients, 182 clinic visits and 18 NS. NSR-SCD vs NSR-CSCDC was 25.9% vs 9.9% (p 0.000002).(Table 1)When the cohort was divided into NSR subgroups. NSR decrease was most significant for the high NSR sub group.For high and middle NSR, NSR-SCD vs NSR-CSCDC were 50.8% vs 28.8% (p 0.002759) and 19.8% vs 4.2% (p 0.001187) respectively.(Table 2)The low subgroup had 0% NSR. Patients with the historically highest NSR had significant decrease in their NSR during CSCDC. There were 170 phone contacts and 122 responses for a 72% response rate. Families were asked to grade their answers in a range of 1-5 with 5 being the highest (top box). Results: 86%, 91% and 92% top box scores for CSCDC patient reporting "extremely satisfied" with CSCDC, "extremely likely" to recommend CSCDC and "extremely likely" to return to CSCDC respectively. 97% responded "yes" that CSCDC improved their individual family SCD care. CSCDC increased adherence to standard HMR. Total patient visits for the time range was 236. There were 56 patients (24%) who attended at least 2 CSCDC. 62% of these repeat attendees received health maintenance evaluations within 4-8 weeks of the recommended time. Conclusion Our CSCDC demonstrates increase in SCD patient compliance with clinic visits, high patient satisfaction and high level of HM adherence to standard. We believe this is an effective model for SCD comprehensive care and this data may be useful to initiate evaluation of a larger patient cohort. Disclosures No relevant conflicts of interest to declare.

2016 ◽  
Vol 10 (2) ◽  
pp. 73-81 ◽  
Author(s):  
Anietie Ekong

The haemoglobinopathies are the most common monogenetic diseases in the world. They include the thalassaemias and sickle cell syndromes. The sickle cell syndromes encompass several abnormal haemoglobin variants, of which homozygosity for the sickle cell gene – that is, sickle cell anaemia is the most common and most severe. Originally characteristic of the tropics and subtropics, recent mobility and migratory trends have meant that the prevalence of sickle cell disease (SCD) has significantly increased in the UK. It is important that GPs have an understanding of this disease, in order to help their patients deal with complications of every-day life. This article will address three main aspects of SCD: diagnosis, health maintenance, and some acute and chronic complications of SCD.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 3411-3411
Author(s):  
Shailja Shah ◽  
Adaeze Nwosu-Iheme ◽  
Alice J. Cohen

Abstract Background: Sickle Cell Disease (SCD), including the subtypes of HbSS(SS) or Hb S beta zero thalassemia(SB0) are characterized by frequent vasoocclusive pain crises (VOC) requiring numerous visits to emergency departments and admissions to the hospital. A NHLBI expert panel recommends that patients(pts) with SCD receive hydroxyurea(H) therapy to improve clinical outcomes. H, approved by the FDA in 1998 for treatment of clinically severe SCA is the only disease modifying agent for sickle cell disease. Its primary mechanism of action is induction of fetal hemoglobin (HbF) which in turn causes inhibition of sickling. As a part of our adult sickle cell comprehensive care program, aggressive education and counseling has been utilized to ensure that eligible adults with SCD are treated with H. The clinical benefits of this program were tracked for its impact on blood parameters and utilization of health care services. Methods: Pts with SS/SB0 over the age of 18 years attending a comprehensive SCD program were tracked for use of H, clinic and ED visits, hospitalizations and transfusions over a period of 12 months. Lab parameters monitored included WBC, Hemoglobin(Hb), MCV , platelets(plts), Hb F level. Dose of H in the steady state is reported in mg/kg . Education about the benefits and side effects was provided utilizing a newly created video, one on one counselling and educational group programs. As part of the yearly visits, H education and compliance were reinforced. Pts were excluded if attempting pregnancy, currently pregnant or breast feeding. Results: We identified 169 pts of which 135 were evaluable with complete data. 89/135 (66%) were on H and 46/135 (34%) not on H. The major barrier to not taking H was patient refusal. Pts on H were divided into two groups, Hb F < 15%(n=54) and Hb F >15% (n=35); 66/89 (75%) were SS , 22/89(25%) SB0. As expected, MCV and HB were higher in pts on H and WBC and plts were lower in pts on H and correlated with higher HbF levels (See Table 1). Table 1. Not on H(n=46) Pts on H with HbF<15% ( n=54) Pts on H with HbF >15%( n=35) WBC(K/uL) 11.3 9.6 8.8 HB(g/dl) 8.4 8.4 9.1 MCV(fL) 90.7 102 113.3 Platelets(K/uL) 367 320 308 HbF (%) 5.5 7.6 18.8 H dose (mg/kg) N/A 22.6 18.6 The number of ED visits was significantly lower on H. Admissions trended lower on H but were not statistically different (see Table 2). Table 2. Pts on H Pts not on H P value ER visits (mean) 1.36 3.15 0.0206 Hospital Admissions (mean) 3.05 3.41 0.6261 Clinic Visits (mean) 6.10 5.89 0.7382 Pts on H had similar ED, clinic visits and admissions with HbF levels of <15% and >15%. The number of pts transfused were as follows: pts not on H 25/46(54%); on H 40/89(45%); and pts with HbF<15% -28/54(52%), while HbF>15%- 12/35(34%). Conclusion: Aggressive education in a community comprehensive care clinic has allowed for a majority of eligible patients with SS/SB0 to utilize H. Use of H has significantly reduced ED visits suggesting uncomplicated VOC can be reduced utilizing H in a community setting .Transfusions were reduced in patients on H especially those with HbF >15%. Mean H dosing did not correlate with higher HbF levels, which raises the question of compliance in some pts. Continued education, monitoring of prescriptions filled and possible higher doses of H may be beneficial in reducing hospitalizations. Disclosures No relevant conflicts of interest to declare.


2019 ◽  
Vol 244 (2) ◽  
pp. 132-146 ◽  
Author(s):  
Nicola Conran ◽  
Lidiane Torres

Sickle cell disease (SCD) is an inherited disease caused by the production of abnormal hemoglobin (Hb) S, whose deoxygenation-induced polymerization results in red blood cell (RBC) sickling and numerous pathophysiological consequences. SCD affects approximately 300,000 newborns worldwide each year and is associated with acute and chronic complications, including frequent painful vaso-occlusive episodes that often require hospitalization. Chronic intravascular hemolysis in SCD significantly reduces vascular nitric oxide (NO) bioavailability, consequently decreasing intracellular signaling via cyclic guanosine monophosphate (cGMP), in turn diminishing vasodilation and contributing to the inflammatory mechanisms that trigger vaso-occlusive processes. Oxidative stress may further reduce NO bioavailability in SCD and can oxidize the intracellular enzyme target of NO, soluble guanylate cyclase (sGC), rendering it inactive. Increasing intracellular cGMP-dependent signaling constitutes an important pharmacological therapeutic approach for SCD with a view to augmenting vasodilation, and reducing inflammatory mechanisms, as well as for increasing the production of anti-polymerizing fetal Hb in erythroid cells. Pharmacological agents under pre-clinical and clinical investigation for SCD include NO-based therapeutics to augment NO bioavailability, as well as heme-dependent sGC stimulators and heme-independent sGC activators that directly stimulate native and oxidized sGC, respectively, therefore bypassing the need for vascular NO delivery. Additionally, the phosphodiesterases (PDEs) that degrade intracellular cyclic nucleotides with specific cellular distributions are attractive drug targets for SCD; PDE9 is highly expressed in hematopoietic cells, making the use of PDE9 inhibitors, originally developed for use in neurological diseases, a potential approach that could rapidly amplify intracellular cGMP concentrations in a relatively tissue-specific manner. Impact statement Sickle cell disease (SCD) is one of the most common inherited diseases and is associated with a reduced life expectancy and acute and chronic complications, including frequent painful vaso-occlusive episodes that often require hospitalization. At present, treatment of SCD is limited to hematopoietic stem cell transplant, transfusion, and limited options for pharmacotherapy, based principally on hydroxyurea therapy. This review highlights the importance of intracellular cGMP-dependent signaling pathways in SCD pathophysiology; modulation of these pathways with soluble guanylate cyclase (sGC) stimulators or phosphodiesterase (PDE) inhibitors could potentially provide vasorelaxation and anti-inflammatory effects, as well as elevate levels of anti-sickling fetal hemoglobin.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2477-2477 ◽  
Author(s):  
Kris Michael Mahadeo ◽  
Suzette Oyeku ◽  
Karen Moody ◽  
Swapmil N. Rajpathak ◽  
Abraham Groner ◽  
...  

Abstract Hydroxyurea therapy is associated with reduced morbidity among patients with sickle cell disease (SCD). Avascular necrosis of the femoral head (AVN) is one potentially debilitating complication of SCD. In this study, we examined the relationship between hydroxyurea use and the prevalence of AVN among children with SCD. We performed a retrospective chart review of 202 children with SCD, aged 10–21 years, followed in the pediatric hematology program at the Children’s Hospital at Montefiore (Bronx, NY) between July 2007 and 2008. Abstracted data included age, ethnicity, SCD genotype, frequency of hospitalization, hip radiograph results, laboratory data and hydroxyurea use. Hip radiographs were performed prospectively as part of SCD health maintenance from 2005–2008. Forty-four patients were excluded because they did not have a screening hip radiograph. Descriptive statistics were calculated for independent variables. T-tests and chi-square tests were used to compare clinical and demographic characteristics of children with and without AVN. Multivariate logistic regressions were used to estimate the odds ratio of having AVN among SCD patients. Our final sample consisted of 158 patients whose demographic characteristics are listed in Table 1. The prevalence of AVN was 16.5% (n=26). Of the clinical variables analyzed, we identified significant associations between the presence of AVN and hydroxyurea use (p=.005), as well as older age (p=.013) (Table 1.) Children with AVN had significantly lower mean lactic dehydrogenase levels (LDH) (p=.04) and higher mean corpuscular volumes (MCV) (p=.012). (Table 2.) After controlling for gender, ethnicity, sickle cell genotype, and frequency of hospitalizations, age was also found to be associated with AVN (OR 1.15, 95% confidence interval (CI): 1.01,1.31, p=0.033). SCD patients on hydroxyurea had higher odds of having AVN compared to non-users (OR 3.51, 95% CI: 1.31, 9.38, p= 0.013). Laboratory values (MCV, Hemoglobin, LDH and Hematocrit) had a high degree of collinearity and were removed from the final model. In summary, the prevalence of AVN in our sample was 16.5%. This is substantially higher than the prevalence of approximately 6% reported by the Cooperative Study of Sickle Cell Disease for comparative age groups in a prospective study1. SCD patients exposed to hydroxyurea were three times more likely to have AVN than those not exposed to this drug. Vaso-occlusive pain crisis is a recognized risk factor for AVN, thus we could expect a higher rate of AVN among patients on hydroxyurea. However, the odds ratio of 3.5 is unexpectedly high and warrants further investigation into the role of hydroxyurea as a risk factor for AVN. Nonetheless, these preliminary results suggest that more stringent screening regimens for AVN may be indicated among this subset of patients. Table 1. Clinical characteristics of patients with and without avn *p&lt;0.05 **p&lt;0.01 No AVN (N =132) AVN (N = 26) Age * 15.7 years 17.4 years Sex Male 64 (49%) 17 (65%) Ethnicity Black 110 (83%) 23 (88%) Hispanic 22 (17%) 3 (12%) HgbSS 84 (64%) 20 (77%) HgbSC 38 (29%) 4 (15%) HgbSBthal0 5(3.8%) 2 (8%) Hgb SC HgbSBthal+ 5 (3.8%) 0 On Hydroxyurea** 38 (29%) 15 (58%) # Hospitalizations 0 60 (45%) 10 (38%) 1–5 64 (49%) 14 (54%) &gt;5 8 (6%) 2 (8%) Table 2. Mean Laboratory Values for Patients With And Without AVN No AVN AVN *p&lt;0.05 (N =132) (N = 26) WBC 10.7 k/uL 10.5 k/uL Hgb 9.4 gm/dL 9.6 gm/dL MCV* 83 fL 89 fL Platelets 381 k/uL 376 k/uL Reticulocyte 7.70% 8.10% Ferritin 369.8 ng/mL 438.7 ng/mL LDH* 471.6 U/L 389 U/L Creatinine 0.6 mg/dL 0.6 mg/dL Hgb F 9.80% 11.30%


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 2221-2221 ◽  
Author(s):  
Veronique Naessens ◽  
Richard Ward ◽  
Kevin H.M. Kuo

Background The phenotype of hemoglobin SC (HbSC) disease is distinct from sickle cell anemia (SCA) (HbSS and S/b0) but management of adults is mostly derived from studies of the latter group. Longitudinal observational studies on the complications and outcomes of hemoglobin SC disease are largely confined to centers outside North America. The unique ethnic composition of our cohort, consisting of mostly Western Africans and West Indians, permits further characterization of the HbSC phenotype. Objective to describe the baseline characteristics and long-term complications of a cohort of adult HbSC patients followed in a Canadian sickle cell comprehensive care center. Methods A retrospective observational cohort study was conducted on all adult patients with HbSC disease attending a sickle cell comprehensive care center in Toronto, Canada from 1994 to 2013. Baseline demographics, acute and chronic complications attributable to sickle cell disease, and laboratory data were collected. Medians were used to describe continuous variables, while percentages or ratios for categorical variables. Logistic regression was used to examine factors influencing the main clinical complications. Results 104 patients were included in the analysis, comprising of 38.5% males and 61.5% females. Median length of follow-up was 3.5 years (1 - 19) and median age at last recorded visit was 35 years (18 - 68). Median baseline hemoglobin was 119 g/L (82 - 153 g/L), hematocrit 0.340 (0.250 - 0.440), and fetal hemoglobin (HbF) fraction 1% (0 - 7.7%). Most frequent complications encountered were retinopathy (55.8%) and symptomatic avascular necrosis (27.9%), followed by painful vaso-occlusive crises requiring emergency room visit (23.1%). Presence of retinopathy was associated with higher baseline hemoglobin (OR 2.72 for every 10 g/L of hemoglobin, p = 0.037) and older age (OR 2.72 for every decade, p < 0.001). Acute chest syndrome (7.7%), priapism (7.5% of men), and renal involvement (8.2%), were less common than reported in the literature, while the rates of venous thromboembolism (8.7%), symptomatic infarctive or hemorrhagic stroke (2.9%) were slightly more common. Median right ventricular systolic pressure on 2D-transthoracic echocardiogram was 29 mmHg (17 – 43 mmHg). No patient underwent a right heart catheterization. Two patients died from septic shock, both at the age of 29. Disease-modifying therapy most often consisted of hydroxyurea (28.8%), followed by exchange transfusion (6.7%) and phlebotomies (5.8%). Hydroxyurea significantly increased the median HbF fraction (from 1% to 2.75%, p = 0.004 by related-samples Wilcoxon signed rank test). Conclusion In this large North American cohort of adult patients, we have again shown that HbSC disease is not as benign as traditionally thought. As such, patients with HbSC disease warrant similar follow-up to that provided to SCA. Retinopathy, avascular necrosis and painful vaso-occlusive crises were the most common complications in our study, albeit lower than in other reported cohorts. The frequent use of hydroxyurea in this cohort is quite unique compared to other sickle cell comprehensive care centers reported in the literature. However, therapeutic phlebotomy is less often used compared to the European experience. We also observed a lower frequency of retinopathy, avascular necrosis, painful vaso-occlusive crises, priapism and acute chest syndrome. Whether this observation is due to hydroxyurea use or to other genetic or environmental factors remains to be determined. Further studies are also required to develop a more evidence-based therapeutic strategy for this genotype of Sickle Cell Disease. Disclosures: No relevant conflicts of interest to declare.


CJEM ◽  
2017 ◽  
Vol 21 (1) ◽  
pp. 55-62 ◽  
Author(s):  
Andrew Binding ◽  
Richard Ward ◽  
Chai Phua ◽  
Veronique Naessens ◽  
Tara O’Brien ◽  
...  

AbstractObjectivesPatients with sickle cell disease (SCD) with vaso-occlusive crises (VOC) often visit the emergency department (ED) for management of painful episodes. The primary objective of this pilot study was to evaluate the acceptability of a short-stay model for treatment of VOC in SCD outside of the ED in Toronto, Canada. Secondary objectives were to assess patient satisfaction of this model, barriers to its use and comparison of clinical outcomes to a historical control.MethodsAdult SCD patients with symptoms of an uncomplicated VOC between October 2014 to July 2016 were managed according to best practice recommendations in a short-stay unit as an alternative to the local emergency room. Primary outcome of time to first analgesia, and secondary outcome of discharge rate were compared to a historical control at a local ED from 2009-2012. Satisfaction and barriers to use of the ambulatory care delivery model were assessed by patient survey.ResultsTwenty-one visits were recorded at the short-stay unit during the study period. Average time to first opiate dose was 23.5 minutes in the short-stay unit compared to 100.3 minutes in the ED (p<0.001). Discharge rate from the short-stay unit was 84.2%. Average patient satisfaction with this model of care was high (>4/5 on Likert scale) except for geographic accessibility (85% response rate, n=18).ConclusionThis study demonstrated high patient satisfaction and acceptability of a short-stay model for treatment of uncomplicated VOC in adult SCD patients in Toronto, the first of its kind in Canada.


Haematologica ◽  
2008 ◽  
Vol 93 (1) ◽  
pp. e20-e20 ◽  
Author(s):  
J.D. Fernandez Aguila ◽  
M. Cabrera Zamora ◽  
O. Alvarez Fernandez ◽  
L. Prieto Jimenez ◽  
O. Mediaceja Vicente ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document